The present invention encompasses type-1 IFN and IFNα-induced PD markerexpression profiles, kits, and methods for identifying such IFNα-inducedPD marker expression profiles. The type-I IFN and IFNα-induced PD markerexpression profiles may also be used in, for example, methods of treating patientshaving a type-I IFN or IFNα- mediated disorder, methods of monitoringdisease progression of patients receiving treatment with a therapeutic agentthat binds to and modulates IFNα activity, identifying patients as candidatesto receive a therapeutic that binds to and neutralizes IFNα activity,and in diagnosing or providing a prognosis to patients having IFNα-induceddisorders.
